TD Asset Management’s Akero Therapeutics AKRO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.2M | Sell |
191,448
-17,400
| -8% | -$928K | 0.01% | 633 |
|
|
2025
Q1 | $8.45M | Buy |
208,848
+39,194
| +23% | +$1.59M | 0.01% | 679 |
|
|
2024
Q4 | $4.72M | Buy |
169,654
+46,200
| +37% | +$1.29M | ﹤0.01% | 805 |
|
|
2024
Q3 | $3.49M | Sell |
123,454
-31,138
| -20% | -$879K | ﹤0.01% | 874 |
|
|
2024
Q2 | $3.63M | Buy |
154,592
+29,600
| +24% | +$694K | ﹤0.01% | 840 |
|
|
2024
Q1 | $3.16M | Buy |
124,992
+30,790
| +33% | +$778K | ﹤0.01% | 887 |
|
|
2023
Q4 | $2.2M | Sell |
94,202
-31,890
| -25% | -$745K | ﹤0.01% | 973 |
|
|
2023
Q3 | $6.38M | Buy |
126,092
+63,346
| +101% | +$3.2M | 0.01% | 671 |
|
|
2023
Q2 | $2.93M | Buy |
62,746
+4,724
| +8% | +$221K | ﹤0.01% | 860 |
|
|
2023
Q1 | $2.22M | Buy |
58,022
+5,600
| +11% | +$214K | ﹤0.01% | 950 |
|
|
2022
Q4 | $2.87M | Buy |
52,422
+33,300
| +174% | +$1.82M | ﹤0.01% | 886 |
|
|
2022
Q3 | $570K | Buy |
+19,122
| New | +$570K | ﹤0.01% | 1271 |
|
|
2022
Q1 | – | Sell |
-25,102
| Closed | -$531K | – | 1484 |
|
|
2021
Q4 | $531K | Hold |
25,102
| – | – | ﹤0.01% | 1372 |
|
|
2021
Q3 | $561K | Hold |
25,102
| – | – | ﹤0.01% | 1366 |
|
|
2021
Q2 | $538K | Hold |
25,102
| – | – | ﹤0.01% | 1374 |
|
|
2021
Q1 | $728K | Buy |
25,102
+5,497
| +28% | +$159K | ﹤0.01% | 1321 |
|
|
2020
Q4 | $506K | Buy |
19,605
+4,000
| +26% | +$103K | ﹤0.01% | 1332 |
|
|
2020
Q3 | $480K | Buy |
15,605
+6,883
| +79% | +$212K | ﹤0.01% | 1250 |
|
|
2020
Q2 | $217K | Buy |
+8,722
| New | +$217K | ﹤0.01% | 1286 |
|
|
2020
Q1 | – | Sell |
-10,322
| Closed | -$229K | – | 1366 |
|
|
2019
Q4 | $229K | Hold |
10,322
| – | – | ﹤0.01% | 1354 |
|
|
2019
Q3 | $235K | Buy |
+10,322
| New | +$235K | ﹤0.01% | 1287 |
|